European and U.S. stock markets showed mixed performances as oil prices declined and technology stocks continued to rise. The CAC 40 index in Paris gained 0.40% to 7,865 points, supported by falling oil prices and bond yields. The drop in crude oil prices was attributed to increased exports from the Middle East and a G7 commitment to release 100 million barrels of oil to the market. This decline in oil prices is seen as a positive for investors, as it could reduce inflationary pressures and ease pressure on interest rates. On Wall Street, the Nasdaq and S&P 500 reached new highs, driven by the artificial intelligence sector. However, 78% of S&P 500 stocks ended the month in the red, with 60% losing at least 5% and 27% falling at least 10%. The S&P 500 lost only about 0.5% in September, but this masked a broader market correction, as nine of the eleven sectors declined. The rise in U.S. Treasury bond yields and an increase in oil prices contributed to the decline in many sectors, including real estate, finance, and cyclical stocks. Nvidia continued to gain ground, approaching a market capitalization of $600 billion, while Microsoft, Tesla, and Amazon also contributed to the overall rise on Wall Street. However, the market remains cautious about the high valuations of technology stocks despite expectations of strong growth in the coming quarters. In Paris, Schneider Electric continued to struggle, losing another 4.51% on Tuesday, following a nearly 10% drop the previous day. The company's acquisition of PTC for $22.6 billion has raised concerns among investors, with JPMorgan lowering its recommendation to "neutral" and reducing its price target. In contrast, Alstom saw a 4.79% increase, driven by a contract with Vingroup to supply 200 subway cars to Hanoi. This deal is expected to strengthen Alstom's position in the Asian market, though the stock remains down about 36% since January. Medincell, a French biopharmaceutical company, surged 16% as it awaits a decision from U.S. health authorities on a new treatment for schizophrenia. Stifel estimates a 90% chance of approval, which could generate up to $1.8 billion in annual sales. The company's previous treatment with Teva saw a 43% increase in sales in the second quarter. The European Union's new delegated regulation on sponsored research, which entered into force in September 2026, has raised questions about its impact on small-cap companies. Meanwhile, the 2027 presidential election has already begun to influence the market, with French rates rising and political risk premiums reaching levels not seen since the sovereign debt crisis. The Federal Reserve's upcoming meeting minutes and consumer credit figures are expected to provide insight into the central bank's stance on interest rates. The minutes from the September meeting, which saw a 0.25% rate increase, will be closely watched, as the recent employment report has reduced expectations of a new rate hike in October. Levi's quarterly results will also serve as an indicator of consumer spending in the U.S.